ideal
vaccin
mucos
pathogen
middl
east
respiratori
syndrom
coronaviru
merscov
confer
sustain
protect
immun
system
mucos
level
evalu
vivo
system
mucos
antigenspecif
immun
respons
induc
singl
intramuscular
intragastr
administr
recombin
adenovir
type
type
base
vaccin
express
merscov
spike
protein
intragastr
administr
either
induc
antigenspecif
igg
neutral
antibodi
serum
howev
antigenspecif
tcell
respons
detect
contrast
singl
intramuscular
dose
function
antigenspecif
tcell
respons
elicit
spleen
pulmonari
lymphocyt
mice
persist
sever
month
radbas
vaccin
administ
intramuscularli
induc
system
humor
immun
respons
neutral
igg
antibodi
result
show
singl
dose
vaccin
repres
appeal
strategi
control
merscov
infect
transmiss
middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
coronaviru
caus
sever
acut
respiratori
syndrom
sar
like
diseas
high
case
fatal
rate
first
describ
decemb
total
laboratoryconfirm
case
report
result
least
death
howev
despit
signific
public
health
threat
vaccin
effect
treatment
option
exist
prevent
potenti
merscov
pandem
similarli
coronavirus
spike
protein
merscov
characterist
structur
compon
virion
membran
form
larg
protrud
spike
surfac
viru
protein
play
import
role
viral
attach
entri
target
cell
coronavirus
sarscov
vaccin
recombin
protein
shown
induc
potent
neutral
antibodi
respons
capabl
inhibit
infect
furthermor
inocul
modifi
vaccinia
viru
ankara
express
merscov
protein
elicit
high
titr
sspecif
neutral
antibodi
mice
highlight
import
protein
viral
propag
furthermor
sdriven
lentivir
transduct
abrog
serum
merscovinfect
patient
indic
sproteinspecif
neutral
antibodi
might
contribut
control
merscov
infect
recombin
adenoviru
rad
vector
wide
use
studi
gene
therapi
vaccin
deliveri
repres
attract
vector
vaccin
develop
characterist
growth
high
titr
manufactur
adequ
space
within
genom
gene
insert
adenovirus
safe
use
vaccin
acut
respiratori
syndrom
test
novel
vaccin
system
numer
infecti
agent
rang
malaria
similar
strategi
base
serolog
distinct
adenovirus
could
allow
success
repeat
immun
type
human
adenovirus
classifi
seven
distinct
speci
ag
differ
set
tissuespecif
tropism
exampl
differ
seen
adenovirus
airway
pathogen
shown
induc
potent
system
respons
wherea
human
serotyp
f
viru
home
gastrointestin
tract
resist
inactiv
gastric
acid
bile
salt
proteas
vector
test
use
intramuscular
im
immun
dnarad
vaccin
regimen
human
clinic
trial
provid
import
proof
concept
adenovirusbas
vaccin
vector
vaccin
yet
test
clinic
howev
natur
tropism
viru
gastrointestin
tract
may
prove
benefici
term
deliv
antigen
otherwis
hostil
gut
environ
tropism
may
allow
oral
administr
vaccin
vector
well
enhanc
induct
mucos
immun
therebi
decreas
likelihood
pathogen
transmiss
via
mucosa
recent
develop
replicationdefici
recombin
vector
express
hiv
envelop
protein
env
strongli
support
hypothesi
construct
shown
induc
hiv
envspecif
system
mucos
immun
respons
primeboost
immun
adenovirus
infect
host
airway
epithelium
replic
mucos
tissu
respiratori
tract
accordingli
pathogen
capabl
elicit
robust
mucos
immun
respons
make
attract
antigen
deliveri
system
fight
mucos
virus
includ
merscov
moreov
protein
repres
promis
target
prevent
therapeut
intervent
merscov
critic
role
earli
stage
viral
infect
evalu
use
two
adenoviru
vector
develop
recombin
vaccin
merscov
replicationdefici
express
merscov
protein
use
immun
mice
via
differ
rout
deliveri
humor
cellular
mucos
immun
respons
anim
examin
assess
potenti
efficaci
vaccin
merscov
infect
sixto
eightweekold
femal
balbc
mice
purchas
anim
care
centr
chines
academi
medic
scienc
beij
china
maintain
specif
pathogenfre
condit
experi
carri
strict
complianc
guid
care
use
laboratori
anim
peopl
republ
china
approv
committe
ethic
anim
experi
chines
centr
diseas
control
prevent
merscov
protein
gene
sequenc
genbank
number
optim
express
adenoviru
vector
use
codon
optimis
softwar
synthes
chemic
codonoptim
gene
merss
clone
gener
pvrcmerss
digest
bglii
bluntend
digest
kpni
releas
merss
fragment
merss
fragment
purifi
agaros
gel
insert
kpniecorv
site
pshuttlecytomegaloviru
cmv
gener
linear
pmei
treat
calf
intestin
alkalin
phosphatas
cotransform
escherichia
coli
electropor
gener
rad
type
plasmid
similarli
merss
fragment
insert
kpniecorv
site
gener
linear
paci
treat
calf
intestin
alkalin
phosphatas
cotransform
e
coli
gener
recombin
plasmid
linear
paci
transfect
cell
use
lipofectamin
accord
manufactur
instruct
life
technolog
carlsbad
ca
rescu
viru
amplifi
cell
similarli
linear
pmei
recombin
viru
rescu
amplifi
cell
virus
purifi
two
round
cscl
ultracentrifug
dialys
buffer
contain
mm
nacl
mm
mgcl
glycerol
mm
trishcl
ph
split
aliquot
preserv
prepar
control
virus
express
green
fluoresc
protein
gfp
report
gene
describ
elsewher
cell
grown
log
phase
infect
multipl
infect
viru
particlescel
hr
postinfect
total
protein
extract
resolv
sdspage
express
merss
analys
western
blot
use
polyclon
rabbit
antiemc
hcovemc
strain
antibodi
protein
extract
cell
infect
gfpcarri
virus
use
neg
control
immunofluoresc
assay
cell
fix
cold
methanol
situ
probe
polyclon
rabbit
antiemc
fitcconjug
goat
antirabbit
antibodi
mice
randomli
distribut
nine
group
n
per
group
vaccin
differ
recombin
virus
differ
rout
describ
tabl
half
mice
group
kill
week
immun
short
term
sera
spleen
lung
intestin
harvest
rest
mice
kill
week
immun
long
term
organ
tissu
similarli
collect
wash
exterior
lung
pb
lung
lavag
sampl
collect
perfus
drain
circulatori
system
ml
pb
remov
blood
lung
lavag
contamin
lung
wash
plasma
antibodi
avoid
small
intestin
larg
intestin
collect
ml
pb
homogen
centrifug
result
supernat
use
analysi
notabl
serial
dilut
rang
sampl
siga
detect
use
pb
contain
tween
pbst
sera
tissu
heatinactiv
min
detect
merscov
protein
receptorbind
domain
rbd
specif
neutral
antibodi
merscov
srbdspecif
igg
iga
antibodi
respons
detect
elisa
briefli
serial
dilut
mous
sera
ad
microtitr
plate
precoat
rrbd
protein
ngwell
plate
incub
hr
wash
six
time
pbst
bound
antibodi
react
horseradish
peroxidaseconjug
antimous
igg
jackson
immunoresearch
laboratori
inc
west
grove
pa
iga
sigmaaldrich
madison
wi
hr
sampl
wash
six
time
pbst
tetramethylbenzidin
pierc
rockford
il
ad
plate
reaction
stop
ad
h
absorb
read
nm
use
elisa
plate
reader
biorad
hercul
ca
cutoff
valu
set
neg
control
titr
neutral
antibodi
immun
mous
sera
determin
use
previous
report
merscov
pseudoviru
system
serum
sampl
serial
dilut
twofold
tissu
cultur
plate
incub
room
temperatur
hr
addit
merscov
pseudoviru
well
result
mixtur
transfer
duplic
well
contain
confluent
cell
hr
incub
luciferas
assay
perform
use
ultra
luminomet
tecan
group
ltd
annedorf
switzerland
experi
carri
triplic
data
express
rel
luminesc
unit
rlu
neutral
antibodi
titr
express
reciproc
highest
serum
dilut
rel
inhibit
rate
calcul
rlu
infect
target
cell
presenc
serumrlu
infect
control
cell
evalu
antigenspecif
tcell
respons
immun
mice
interferonc
ifnc
enzymelink
immunospot
assay
perform
describ
previous
briefli
plate
coat
well
mgml
antimous
ifnc
antibodi
bd
pharmingen
san
jose
ca
steril
condit
incub
overnight
humidifi
chamber
wash
steril
pbst
plate
block
hr
room
temperatur
freshli
harvest
mous
splenocyt
cellswel
pulmonari
lymphocyt
cellswel
stimul
co
synthes
peptid
librari
overlap
merscov
srbd
amino
acid
ad
biotinyl
detect
antibodi
bd
pharmingen
streptavidinhorseradish
peroxidas
blot
develop
addit
substrat
solut
plate
incub
dark
min
ifnc
spotform
cell
could
count
phorbol
ionomycin
ad
posit
control
group
wherea
neg
control
group
receiv
stimuli
ig
c
im
im
ig
ig
e
im
im
f
ig
ig
number
peptidespecif
ifncsecret
cell
calcul
subtract
neg
control
valu
spotform
cell
count
cytometr
bead
array
analysi
conduct
investig
level
helper
type
cytokin
secret
mice
week
immun
brief
splenocyt
per
well
eight
mice
group
distribut
plate
stimul
mgml
pool
rbd
peptid
plate
incub
hr
supernat
harvest
concentr
cytokin
includ
tumour
necrosi
factora
tnfa
ifnc
measur
use
mous
cytokin
kit
bd
bioscienc
san
jose
ca
fac
calibur
flow
cytomet
becton
dickinson
franklin
lake
nj
data
analys
use
fcap
array
softwar
becton
dickinson
statist
analys
perform
oneway
analysi
varianc
use
graphpad
prism
softwar
p
valu
consid
signific
adenoviru
plasmid
carri
human
codon
optim
protein
gene
merscov
construct
homogen
recombin
shuttl
backbon
plasmid
escherichia
coli
adenoviru
vector
rescu
amplifi
purifi
use
tradit
method
schemat
detail
structur
recombin
virus
shown
fig
express
merss
cell
detect
western
blot
fig
indirect
immunofluoresc
fig
two
promin
band
detect
western
blot
higher
band
thought
fulllength
protein
mw
glycosyl
pattern
lower
band
mw
subunit
cleavag
host
cell
proteas
size
indic
band
bigger
predict
one
base
nucleotid
sequenc
consist
result
shown
anoth
previou
report
verifi
fivefold
dose
vector
express
merscov
antigen
similar
level
fig
c
compar
immunogen
vector
analys
mice
use
variou
regimen
antigenspecif
humor
igg
neutral
antibodi
product
induc
singl
vaccin
evalu
abil
induc
system
humor
immun
respons
via
intragastr
ig
im
inject
collect
mous
sera
differ
timepoint
week
postvaccin
screen
humor
igg
merscov
srbd
use
elisa
notabl
dosag
vaccin
fivefold
vaccin
studi
tabl
express
level
antigen
vaccin
vitro
compar
fivefold
dose
vaccin
virus
induc
strong
rbdspecif
igg
antibodi
respons
week
short
term
vaccin
fig
merscov
srbdspecif
igg
respons
induc
significantli
higher
mice
immun
im
inject
compar
mice
receiv
either
via
ig
rout
p
signific
differ
seen
igg
titr
mice
vaccin
intramuscularli
p
next
assess
capac
induc
longterm
antibodi
respons
mice
vaccin
ig
im
inject
expect
merssspecif
igg
could
still
detect
week
vaccin
except
ig
vaccin
group
fig
rbdspecif
igg
titr
induc
im
ig
im
vaccin
group
signific
howev
differ
among
three
group
signific
p
investig
effect
vaccin
rout
abil
admerss
induc
neutral
antibodi
neutral
capac
mous
sera
collect
four
treatment
group
analys
use
pseudovirusbas
inhibit
assay
week
postvaccin
ig
im
vaccin
group
exhibit
strong
neutral
antibodi
respons
merscov
interestingli
differ
neutral
titr
evid
ig
im
vaccin
group
p
fig
intramuscular
vaccin
induc
significantli
higher
level
neutral
antibodi
im
vaccin
p
differ
seen
ig
vaccin
group
ig
im
adgfp
control
group
induc
background
level
neutral
antibodi
assess
abil
recombin
virus
induc
longterm
neutral
antibodi
mice
kill
week
vaccin
analys
agreement
igg
result
neutral
antibodi
could
still
detect
week
vaccin
except
ig
vaccin
group
fig
neutral
antibodi
titr
induc
im
ig
im
vaccin
group
significantli
higher
either
vaccin
group
assess
abil
virus
induc
local
mucos
immun
respons
via
differ
vaccin
rout
mucos
iga
respons
analys
sera
lung
lavag
fluid
intestin
vaccin
mice
elisa
result
indic
vaccin
induc
lower
detect
merssspecif
iga
respons
among
tissu
organ
examin
data
shown
overal
iga
detect
may
underestim
limit
amount
fluid
collect
sampl
dilut
factor
dilut
studi
optim
assay
would
warrant
evalu
effect
ig
im
vaccin
cellular
immun
count
ifncproduc
cell
splenocyt
immun
mice
week
postimmun
im
im
vaccin
induc
signific
ifncsecret
tcell
respons
fig
respons
similar
level
two
test
group
respons
substanti
stronger
mice
vaccin
intramuscularli
compar
vaccin
intragastr
either
p
differ
seen
group
administ
either
vaccin
virus
similar
result
seen
longterm
observ
week
fig
expect
antigenspecif
cellular
immun
respons
detect
spleen
lung
mice
immun
control
vector
result
suggest
cytokin
profil
spleen
cell
immun
mice
week
analys
stimul
rbdspecif
peptid
cytometr
bead
array
analysi
splenocyt
mice
immun
either
via
im
rout
produc
ifnc
fig
fig
fig
tnfa
fig
much
higher
level
produc
via
ig
rout
cytokin
background
level
seen
mockinfect
control
vectorinfect
group
splenocyt
mice
immun
im
induc
significantli
higher
level
p
ifnc
fig
fig
fig
tnfa
fig
compar
im
group
detect
none
group
data
shown
data
indic
higher
sustain
frequenc
sspecif
cytokineproduc
cell
induc
vaccin
via
im
rout
first
step
toward
develop
new
vaccin
prevent
merscov
infect
transmiss
present
studi
explor
immunogen
mice
follow
singl
im
ig
inject
data
suggest
singl
administr
im
ig
inject
induc
antigenspecif
system
igg
product
neutral
antibodi
respons
potent
cytokin
secret
balbc
mice
n
per
group
immun
differ
immunogen
differ
rout
exposur
describ
tabl
four
week
postimmun
short
term
half
mice
group
kill
variou
tissu
organ
analys
antibodi
respons
adenoviru
merss
elisa
remain
mice
kill
week
postimmun
long
term
analys
shortterm
group
shortterm
antirecombin
receptorbind
domain
rrbd
igg
serum
b
longterm
antirrbd
igg
serum
statist
signific
differ
indic
follow
p
p
p
figur
neutral
antibodi
respons
immun
mice
sera
collect
week
b
postvaccin
heatinactiv
examin
neutral
antibodi
use
middl
east
respiratori
syndrom
coronaviru
merscov
pseudoviru
system
viru
neutral
titr
defin
dilut
rel
inhibit
rate
data
present
mean
ae
standard
error
mean
sem
statist
signific
differ
indic
follow
p
p
p
spleenresid
lymphocyt
mucos
pulmonari
lymphocyt
ifnc
secret
immun
mice
furthermor
higher
dose
induc
humor
cellular
immun
respons
similar
follow
im
challeng
suggest
good
substitut
induct
system
immun
howev
antigenspecif
immun
sera
mucos
site
dramat
higher
follow
im
vaccin
group
novel
vector
possess
natur
mucos
tropism
may
advantag
common
vector
term
administr
safeti
vaccin
potenc
gut
tropism
indic
vector
may
effici
induc
mucos
immun
respons
administ
via
oral
ig
rout
singl
ig
dose
induc
signific
humor
immun
serum
howev
signific
antigenspecif
tcell
respons
detect
spleen
pulmonari
lymphocyt
mice
immun
intragastr
contrast
studi
suggest
mucos
administr
advantag
induc
tlymphocyt
respons
mucos
surfac
addit
studi
necessari
fulli
defin
differ
underli
mechan
may
improv
abil
design
vaccin
regimen
target
polyfunct
system
mucos
immun
particular
infecti
agent
mucos
immun
consid
import
protect
mani
infecti
diseas
mucos
surfac
first
line
defenc
major
pathogen
includ
merscov
although
recent
progress
made
robust
stimul
mucos
immun
remain
difficult
sever
approach
use
elicit
mucos
immun
respons
use
vaccin
intranas
immun
vaccin
gener
stronger
iga
respons
system
mucos
compart
im
immun
mice
howev
safeti
concern
may
limit
use
approach
human
addit
oral
immun
conveni
way
deliv
mucos
vaccin
heterolog
oral
ileal
prime
follow
im
boost
elicit
enhanc
intestin
mucos
cellular
immun
studi
found
antigenspecif
igg
neutral
antibodi
induc
ig
administr
vaccin
express
protein
merscov
immun
strategi
associ
increas
safeti
applic
rel
oral
challeng
make
excel
choic
futur
vaccin
develop
effort
furthermor
increas
evid
support
role
dromedari
camel
reservoir
merscov
vaccin
strategi
may
hold
promis
develop
prevent
vaccin
target
anim
reservoir
may
effect
approach
elimin
transmiss
merscov
human
virusspecif
cell
requir
pathogen
clearanc
follow
primari
respiratori
cov
infect
one
recent
report
also
show
virusspecif
cell
primeboost
immun
protect
suscept
mice
lethal
sarscov
challeng
wide
accept
system
immun
proteinor
peptidebas
vaccin
induc
weak
shortterm
cellular
immun
respons
rrbd
subunit
immun
studi
report
sustain
mucos
well
system
cellular
immun
respons
induc
mice
singl
administr
via
im
rout
fig
togeth
studi
demonstr
possibl
gener
sustain
mucos
system
tcellmedi
immun
use
merscov
vaccin
howev
optim
necessari
advanc
human
clinic
trial
previou
report
show
rout
vaccin
critic
impact
magnitud
also
phenotyp
traffick
antigenspecif
immun
mice
despit
mani
attract
featur
mucos
vaccin
often
proven
difficult
practic
stimul
strong
immun
respons
protect
mucos
administr
antigen
oral
ig
immun
vector
target
digest
epithelium
induct
mucos
system
immun
well
document
studi
suggest
mucos
rout
vaccin
vector
may
use
optim
mucos
cellular
immun
studi
found
rout
rad
vector
deliveri
critic
impact
system
mucos
immun
particular
im
rad
immun
consist
gener
highlevel
tlymphocyt
respons
among
system
mucos
compart
contrast
ig
immun
gener
detect
lymphocyt
serum
mucos
site
find
suggest
singl
im
dose
induc
strong
persist
complementari
system
mucos
immun
repres
appeal
strategi
control
merscov
transmiss
continu
develop
appropri
formul
enter
coat
nanoparticl
might
allow
vector
amen
clinic
applic
overal
examin
effect
administr
rout
immun
respons
use
singl
dose
vector
vaccin
agent
studi
prepar
manuscript
differ
group
report
antibodi
respons
protein
suffici
neutral
merscov
vitro
respons
could
induc
use
im
vaccin
merscov
candid
vaccin
follow
secondari
intranas
boost
week
later
result
indic
singl
im
ig
administr
induc
santigenspecif
system
mucos
immun
furthermor
signific
sustain
neutral
antibodi
product
well
cellmedi
immun
could
elicit
vaccin
via
intramuscular
rout
fulllength
protein
avail
hand
evolut
antibodi
respons
igg
iga
limit
rbdspecif
antibodi
understand
sproteinspecif
antibodi
may
play
role
neutral
protect
infect
although
major
rbdspecif
antibodi
neutral
addit
protocol
iga
assay
evalu
mucos
immun
studi
need
optim
although
studi
necessari
evalu
protect
efficaci
vector
human
dromedari
camel
result
strongli
support
role
merss
antigen
safe
effect
strategi
merscov
prevent
immun
elicit
radbas
merscov
vaccin
